PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Scoring Tool Ranks Pediatric Vancomycin PK Models for Precision Dosing

vancomycinglycopeptide antibioticspopulation pharmacokineticsmodel-informed precision dosingtherapeutic drug monitoringneonatespediatricsAUC-guided dosingsystematic review Pharmacokinetics / TDM

Background Information

Optimize vancomycin dosing with precision models in young patients.

Vancomycin dosing in neonates and children is challenging due to variability in pharmacokinetics, making precision dosing crucial for efficacy and safety. Among 112 models identified, the study highlights the Chen (2023) model as the best for neonatal and pediatric populations based on comprehensive evaluation. The review provides a standardized tool for selecting appropriate pharmacokinetic models, enhancing model-informed precision dosing for vancomycin in young patients. The Chen (2023) popPK model is recommended for vancomycin precision dosing in neonates and children.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Vander Elst Z, Spiessens PJ, Vanneste D, Dia N, Gijsen M, Spriet I, Allegaert K, Dreesen E, Smits A

Citation: Vander Elst Z, Spiessens PJ, Vanneste D, et al. Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children. British journal of clinical pharmacology. 2026;92(7):2028-2048. doi:10.1002/bcp.70530

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.